1,25-dihydroxycholecalciferol and parathyroid hormone like factors.3 Hypercalcaemia in haematological malignancies is a well described complication, and humoral factors involved in the pathogenesis are still being investigated, but this presentation is uncommon in this rare subspecialty of Hodgkin's disease. Reports have described hypercalcaemia with no evidence of skeletal metastases or bone marrow abnormalities in Hodgkin's disease,4 " and established evidence has shown that 1,25-dihydroxycholecalciferol is the factor produced by the tumour."8 However, Jacobsen et al suggest that 1,25-dihydroxycholecalciferol cannot be the sole humoral mediator of hypercalcaemia in Hodgkin's disease as shown by in vitro bone resorption studies.9 Bone resorption activity in a tumour conditioned medium greatly exceeded that attributed to the measured 1 ,25-dihydroxycholecalciferol; the resorption shown by the medium was dependent on enhanced cycloxygenase activity that was probably produced by a co-factor.
The identification of PTHRP has helped to explain some of the features in hypercalcaemia of malignancy, as it has been implicated as a possible contributing factor in this condi- This case report raises several interesting points. First, CMV should be considered in patients in whom GvHD does not respond to appropriate treatment. In this case, CMV viraemia was concomitant with the relapse in GvHD and this seems to support the hypothesis that CMV may increase the severity of GvHD by synergistically enhancing the graft versus host reaction. Second, the differentiation of GvHD from CMV is difficult histologically and immunohistochemistry is useful in this regard. Third, in spite of detectable CMV viraemia, repeated urine and throat swab specimens were negative for CMV by culture until the terminal stages of the illness (74 days after BMT).
Finally, CMV viraemia was not detectable by culture 56 days after BMT. However, the virus was detectable in the peripheral blood by PCR up to the time of death, and death was caused by disseminated CMV infection. Herman et al have recently suggested that the PCR may have a role in the early detection of CMV in the period immediately after transplantation before any clinical symptoms of viraemia or GvHD are evident. 8 Using agarose gel electrophoresis with ethidium bromide staining to detect the amplified PCR product, the technique that we used does not detect CMV DNA in the peripheral blood of healthy seropositive subjects. Furthermore, we have so far studied 22 transplant recipients, 13 of whom were seropositive for CMV before surgery, and have obtained negative PCR results for CMV at several time intervals after transplantation in 21 patients, all of whom were shown not to have been actively infected with CMV. This preliminary evidence suggests that PCR may be able to differentiate clinically important active CMV infection from subclinical infection. As profound immunosuppression may facilitate the reactivation of latent CMV, the differentiation of active CMV infection by PCR may be important in the management of immunosuppressed patients.
